The protease medicines company

Our programs:

The protease advantage
CB 4332 – SQ Enhanced Complement Factor I

Latest news

Oct 13, 2021

Catalyst Biosciences Announces Chief Financial Officer Transition

Sep 28, 2021

FDA Grants Catalyst Biosciences Orphan Drug Designation for MarzAA for the Treatment of Factor VII Deficiency

Sep 24, 2021

Catalyst Biosciences to Present at the Cantor Global Healthcare Conference

X